Gyre Therapeutics, Inc. Common Stock (GYRE) — 分析摘要
Gyre Therapeutics, Inc. Common Stock（GYRE）的市值为727.92百万美元，最近一年的营收同比增长了+10.2%。净利润率为8.5%。当前市盈率为-25.8倍。
核心要点
- 营收同比变化+10.2%
- 净利润率8.5%
- 市盈率-25.8倍
与PHARMACEUTICAL PREPARATIONS板块的其他公司相比，GYRE的营收增长为+10.2%，市盈率为-25.8倍。
Gyre Therapeutics, Inc. Common Stock (GYRE)
前收盘价 2026-10-12 · 市场数据 POLYGON · 财务数据 SEC EDGAR
红旗与风险提示高风险信号
存在多项实质性红旗，在依赖任何估值输出前应先重点核查这些风险。
净利润由上一期盈利转为亏损。
营业利润率为 -21.7% — 经营亏损显著
净利率为 -23.3% — 亏损显著
最新报表显示自由现金流为负。
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
行业
PHARMACEUTICAL PREPARATIONS
员工人数
618
总部
SAN DIEGO, CA
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
年度每股股息
N/A
股息收益率
N/A
股息历史
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。